Fluxergy, Inc. of Irvine, CA at MEDICA 2020 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

Fluxergy, Inc.

13766, Alton Parkway Suite 150, 92618 Irvine, CA
USA
Telephone +1 949 3054201206
Fax +1 949 3051388
info@fluxergy.com

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

Media files

Contact

Dr. Ali Tinazli

Chief Commercial Officer

13766 Alton Parkway
92618 Irvine, USA

Phone
+13104671112

Email
atinazli@fluxergy.com

Visit us

Unsettled / NN

16.11.2020

Topic

all-day

Fluxergy COVID-19 Sample-to-Answer RT-PCR Test*

The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy’s CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the
SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests
with patient samples by researchers at University of California San Diego (UCSD).

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

More Less

all-day

How the Coronavirus SARS-CoV-2 Exposes the Flaws of Current Health Testing

The rapid spread of COVID-19, which has the potential to become a once-in-a-century pandemic,
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

More Less

17.11.2020

Topic

all-day

Fluxergy COVID-19 Sample-to-Answer RT-PCR Test*

The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy’s CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the
SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests
with patient samples by researchers at University of California San Diego (UCSD).

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

More Less

all-day

How the Coronavirus SARS-CoV-2 Exposes the Flaws of Current Health Testing

The rapid spread of COVID-19, which has the potential to become a once-in-a-century pandemic,
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

More Less

18.11.2020

Topic

all-day

Fluxergy COVID-19 Sample-to-Answer RT-PCR Test*

The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy’s CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the
SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests
with patient samples by researchers at University of California San Diego (UCSD).

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

More Less

all-day

How the Coronavirus SARS-CoV-2 Exposes the Flaws of Current Health Testing

The rapid spread of COVID-19, which has the potential to become a once-in-a-century pandemic,
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

More Less

19.11.2020

Topic

all-day

Fluxergy COVID-19 Sample-to-Answer RT-PCR Test*

The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy’s CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the
SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests
with patient samples by researchers at University of California San Diego (UCSD).

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

More Less

all-day

How the Coronavirus SARS-CoV-2 Exposes the Flaws of Current Health Testing

The rapid spread of COVID-19, which has the potential to become a once-in-a-century pandemic,
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

More Less

Our range of products

Product categories

  • 03  Diagnostic tests
  • 03.01  Clinical chemistry
  • 03.01.03  Urinalysis equipment and systems

Urinalysis equipment and systems

  • 03  Diagnostic tests
  • 03.01  Clinical chemistry
  • 03.01.04  Rapid tests in clinical chemistry

Rapid tests in clinical chemistry

  • 03  Diagnostic tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.01  Immuno assay testing

Immuno assay testing

  • 03  Diagnostic tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.02  Diagnostic rapid tests
  • 03  Diagnostic tests
  • 03.03  Haematology / histology / cytology testing
  • 03.03.04  Other haematology / histology / cytology testing

Other haematology / histology / cytology testing

  • 03  Diagnostic tests
  • 03.04  Microbiology testing
  • 03.04.03  Rapid tests in microbiology

Rapid tests in microbiology

  • 03  Diagnostic tests
  • 03.05  Infectious immunology testing
  • 03.05.02  Microbiological diagnosis, virology, equipment and systems for

Microbiological diagnosis, virology, equipment and systems for

  • 03  Diagnostic tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.01  DNA testing
  • 03  Diagnostic tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.02  Molecular biomarkers
  • 03  Diagnostic tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.03  Polymerase chain reaction (PCR)
  • 06  Information and communication technology
  • 06.02  mHealth, mobile IT, wireless technologies (Bluetooth, WI-FI)

mHealth, mobile IT, wireless technologies (Bluetooth, WI-FI)

  • 06  Information and communication technology
  • 06.04  eHealth, telemedicine / telematics / telemetry

eHealth, telemedicine / telematics / telemetry

Our products

Product category: Diagnostic rapid tests, Microbiological diagnosis, virology, equipment and systems for, Polymerase chain reaction (PCR), DNA testing, Molecular biomarkers, mHealth, mobile IT, wireless technologies (Bluetooth, WI-FI), eHealth, telemedicine / telematics / telemetry

Fluxergy COVID-19 Sample-to-Answer RT-PCR Test*

The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy’s CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the
SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests
with patient samples by researchers at University of California San Diego (UCSD).

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities
are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future evenets could differ materially from those anticipated in such statements.

More Less

Product category: Polymerase chain reaction (PCR), Urinalysis equipment and systems, Rapid tests in clinical chemistry, Immuno assay testing, Diagnostic rapid tests, Other haematology / histology / cytology testing, Rapid tests in microbiology, Microbiological diagnosis, virology, equipment and systems for, DNA testing, Molecular biomarkers, mHealth, mobile IT, wireless technologies (Bluetooth, WI-FI), eHealth, telemedicine / telematics / telemetry

Fluxergy Analyzer*

Our core device, the Fluxergy Analyzer, is a highly-integrated sensor system along with our sophisticated analysis algorithms. The Fluxergy Analyzer can be used for laboratory analyses such as PCR, ELISA, ISE, and cytometry-based assays.

Ruggedized Exterior Casing
The Fluxergy Analyzer features a smooth monocoque casing that is both lightweight and robust.

Active Cooling System
The active cooling system allows the Fluxergy Analyzer to rapidly manipulate the subjected sample to significantly decrease test times.

Quick Battery Hookup
Whether you are in a resource-limited setting or at a high-tech laboratory, the Fluxergy Analyzer can always have power. Simply hook up a compatible battery pack and realize the portability of the Fluxergy Analyzer system.

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities
are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

More Less

Company news

Date

Topic

Download

Nov 13, 2020

How to Run a Fluxergy PCR Test

More Less

Nov 13, 2020

Video: Tej Patel: Why We Need Multimodal Testing

More Less

Nov 13, 2020

Video: How Fluxergy Could Disrupt and Transform the Healthcare Industry

More Less

Jun 30, 2020

Fluxergy, Mass General Brigham Partner to Evaluate Rapid COVID-19 Molecular Testing System

More Less

About us

Company details

Fluxergy, founded in 2013, seeks to provide a portable, easy-to-use sample-to-answer platform that enables clinicians to cost-effectively conduct a wide range of sophisticated multiplex and multimodal in vitro diagnostic tests (different types of tests all at once, up to 30 targets) at the point-of-care.

The Fluxergy Diagnostic Testing System consists of The Fluxergy Card, a single-use “lab-on-chip” consumable test cartridge; the Fluxergy Analyzer, which conducts the testing process, and; the FluxergyWorks software, used by the clinician/operator to review and interpret the test data. The Fluxergy Cards are designed to be very cost-effective and scalable, using proprietary printed circuit board (PCB) manufacturing and microfluidics technologies. FluxergyWorks enables organizations to link together via the Cloud as many as 256 Fluxergy Analyzers for centralized data reporting.

Please visit fluxergy.com for more information.

Contact: Dr. Ali Tinazli, atinazli@fluxergy.com

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this video regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

More Less

Company data

Number of employees

50-99

Foundation

2013

Area of business
  • Electromedical equipment / Medical Technology
  • Laboratory Equipment
  • Diagnostics